Aarti Drugs Reports Q4 & FY25 Business & Financial Performance: Revenue Grew by 9% to Rs. 679 Crores

Aarti Drugs Limited, a Mumbai based diversified pharmaceutical company, has announced its audited financial results for the quarter and full year ending 31st March 2025. The company reported a 9% YoY growth in revenue for Q4FY25, reaching Rs. 678.6 crores. The EBITDA stood at Rs. 95.2 crores, a growth of 10% YoY, with an EBITDA margin of 14%. The PAT stood at Rs. 62.8 crores, an increase of 33% YoY, with a PAT margin of 9.2%. However, the full-year revenue showed a 5% decline. The API business contributed ~39% to total APl sales, and the formulation segment reported a 4% YoY decline in revenue. The company has also entered into a power purchase agreement and updated on the lifting of Import Alert 66-40 by US FDA.